Dermata Therapeutics, Inc. (DRMA): who owns it and who trades it
As of Nov 16, 2026, DRMA insiders reported 1 open-market sale worth $13 and 1 purchase worth $1.3K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Kathleen D. Scott (Director), with $13. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Dermata Therapeutics
From the latest filingsOverall: more buying than selling. Famous investors mostly bought. Insiders was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, DRMA insiders reported $1.3K of open-market purchases and $13 of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | Kathleen D. Scott | Director | Sale | 11 | $1.19 | $13 | Form 4 |
| Feb 17, 2026 | Munera Maria E Bedoya-Toro | Vice president | Purchase | 1,000 | $1.27 | $1.3K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Munera Maria E Bedoya-Toro | SVP, Regulatory Affairs | $1.3K | – | Feb 17, 2026 |
| Kathleen D. Scott | Director | – | $13 | Jun 16, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
DRMA short interest
Low short interest. 2.1% of DRMA shares are sold short: about 1 share in 48. Over the last 12 reports the number of shares short went down 26%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 84,233 DRMA shares were sold short, 2.1% of the shares outstanding, up 9.0% from the report before. At the average daily volume of 406,501 shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 84,233 | 2.09% | +9% | 406,501 | 1.0 |
| Oct 15, 2026 | 77,279 | 1.92% | -9% | 15.41M | 1.0 |
| Sep 30, 2026 | 84,484 | 2.10% | -30% | 23,429 | 3.6 |
| Sep 15, 2026 | 120,024 | 2.98% | -28% | 37,704 | 3.2 |
| Aug 31, 2026 | 167,251 | 4.16% | -54% | 142,173 | 1.2 |
| Aug 14, 2026 | 366,825 | 9.12% | +623% | 4.13M | 1.0 |
| Jul 31, 2026 | 50,755 | 1.26% | -22% | 48,748 | 1.0 |
| Jul 15, 2026 | 64,856 | 1.61% | -51% | 88,114 | 1.0 |
| Jun 30, 2026 | 131,494 | 3.27% | +41% | 106,781 | 1.2 |
| Jun 15, 2026 | 92,975 | 2.31% | -4% | 59,670 | 1.6 |
| May 29, 2026 | 96,498 | 2.40% | -16% | 47,583 | 2.0 |
| May 15, 2026 | 114,588 | 2.85% | -24% | 52,304 | 2.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Dermata Therapeutics company events
Dermata Therapeutics filed 13 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, auditor). The latest was on Nov 10, 2026.
- Nov 10, 2026ResultsReleased financial results. Filing
- Oct 29, 2026AnnouncementDermata Therapeutics, Inc. issued a press release announcing enrollment of the first participant in a clinical trial evaluating Tome Clearing Treatment, the Company’s once-weekly acne treatment, in participants with acne. Filing
- Aug 17, 2026AgreementDermata Therapeutics, Inc. entered into securities purchase agreements with certain institutional and accredited investors, for the issuance and sale in a private placement of (i) 933,064 shares of the Company’s common stock, par value $0.0001 per share, (ii) pre-funded warrants to purchase up to… Filing
- Aug 11, 2026ResultsReleased financial results. Filing
- Aug 5, 2026AnnouncementDermata Therapeutics, Inc. issued a press release disclosing the Company’s anticipated launch date for its first commercial product, Tome Foundational Treatment. Filing
- May 27, 2026LeadershipDermata Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders. Filing
- May 13, 2026ResultsReleased financial results. Filing
- Mar 26, 2026ResultsReleased financial results. Filing
- Feb 25, 2026LeadershipMary Fisher provided Dermata Therapeutics, Inc. with notice of her resignation from the Board of Directors, including from her role on any committees thereof, effective March 31, 2026. Filing
- Feb 3, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
- Jan 27, 2026AnnouncementDermata Therapeutics, Inc. filed a prospectus supplement to increase the maximum aggregate offering amount of the shares of the Company’s common stock, par value $0.0001 per share, issuable under the At The Market Offering Agreement with H.C. Wainwright & Co., LLC, dated June 7, 2024, by an… Filing
- Dec 29, 2025AgreementDermata Therapeutics, Inc. entered into a securities purchase agreement with certain institutional and accredited investors for the issuance and sale in a private placement of (i) 1,484,312 shares of the Company’s common stock, par value $0.0001 per share, (ii) pre-funded warrants to purchase up to… Filing
- Nov 18, 2025AgreementEnded an important agreement. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Dermata Therapeutics financials
Famous investors that hold DRMA
1 of the 50 well-known investors we track reported holding DRMA in their latest 13F filing. The largest position is Ken Griffin's, worth $36.1K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 32,796 | $36.1K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named DRMA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 2, 2026 | BIGGER CAPITAL FUND L P | 13G | 4.9% |
| Nov 2, 2026 | BIGGER CAPITAL FUND L P | 13G | 4.9% |
Questions about Dermata Therapeutics, Inc. (DRMA) stock
Are DRMA insiders buying or selling?
In the last 12 months, DRMA insiders reported 1 open-market purchase worth $1.3K and 1 sale worth $13. The latest trade was on Jun 16, 2026. See every trade.
What is the short interest in DRMA?
As of Oct 30, 2026, 84,233 DRMA shares were sold short, 2.1% of the shares outstanding, up 9.0% from the report before. At the average daily volume of 406,501 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Which famous investors hold DRMA?
1 of the 50 well-known investors we track reported DRMA in their latest 13F filing, including Ken Griffin. The largest position is worth $36.1K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.